Literature DB >> 11229825

Determination of plasma aprotinin levels by functional and immunologic assays.

R A Cardigan1, I J Mackie, C Gippner-Steppert, M Jochum, D Royston, M J Gallimore.   

Abstract

We compared a functional (amidolytic) and an enzyme-linked immunosorbent assay (ELISA) method for determining aprotinin concentration in 82 plasma samples obtained from patients undergoing cardiac surgery with aprotinin therapy. There was good correlation between methods (r = 0.87); however, aprotinin measurements by chromogenic assay were significantly higher than by ELISA [234 +/- 104 kallikrein inhibitory units (KIU)/ml versus 155 +/- 88 KIU/ml; P = 0.0001]. This appeared to be attributable to differences in the potency of the material used to standardize the assays. When results were corrected to allow for potency of the standard, there was no significant difference between chromogenic and ELISA methods (234 +/- 104 KIU/ml versus 240 +/- 137 KIU/ ml), although the ELISA results tended to be higher in some samples. These data suggest that aprotinin concentrations measured by these methods cannot be used interchangeably, and care must be taken when interpreting data from studies measuring aprotinin.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11229825     DOI: 10.1097/00001721-200101000-00006

Source DB:  PubMed          Journal:  Blood Coagul Fibrinolysis        ISSN: 0957-5235            Impact factor:   1.276


  3 in total

1.  Plasmin inhibition increases MMP-9 activity and decreases vein wall stiffness during venous thrombosis resolution.

Authors:  Nicholas A Dewyer; Vikram Sood; Erin M Lynch; Catherine E Luke; Gilbert R Upchurch; Thomas W Wakefield; Steven Kunkel; Peter K Henke
Journal:  J Surg Res       Date:  2007-06-14       Impact factor: 2.192

2.  Urinary aprotinin as a predictor of acute kidney injury after cardiac surgery in children receiving aprotinin therapy.

Authors:  Mai T Nguyen; Catherine L Dent; Gary F Ross; Nathan Harris; Peter B Manning; Mark M Mitsnefes; Prasad Devarajan
Journal:  Pediatr Nephrol       Date:  2008-05-28       Impact factor: 3.714

3.  Optimal dose of aprotinin for neuroprotection and renal function in a piglet survival model.

Authors:  Yusuke Iwata; Toru Okamura; Nobuyuki Ishibashi; David Zurakowski; Hart G W Lidov; Richard A Jonas
Journal:  J Thorac Cardiovasc Surg       Date:  2009-04-21       Impact factor: 5.209

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.